Jenny Furlanetto

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani et al. · The Lancet Oncology · 2017 · 2.1K citations

Medicine, Immunology, Oncology +14

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 694 citations

Medicine, Oncology, Pharmacology +16

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Cancer Biology, Oncology +16

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Sibylle Loibl, Jens Huober, Michael Braun et al. · Annals of Oncology · 2022 · 244 citations

Medicine, Oncology, Breast Oncology +9

Central venous access in oncology: ESMO Clinical Practice Guidelines

Berta Sousa, Jenny Furlanetto, Margaret Hutka et al. · Annals of Oncology · 2015 · 187 citations · Full text

Medicine, Oncology, Surgery +13